Highlights and Quick Summary
- EBIT Margin for the quarter ending September 30, 2023 was 0.0% (a NaN% decrease compared to previous quarter)
- Year-over-year quarterly EBIT Margin decreased by NaN%
- Annual EBIT Margin for 2022 was 0.0% (a NaN% decrease from previous year)
- Annual EBIT Margin for 2021 was 0.0% (a -100.0% decrease from previous year)
- Twelve month EBIT Margin ending September 30, 2023 was 0.0% (a NaN% decrease compared to previous quarter)
- Twelve month trailing EBIT Margin decreased by NaN% year-over-year
Trailing EBIT Margin for the last four month:
30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
---|---|---|---|
0.0% | 0.0% | 0.0% | 0.0% |
Visit stockrow.com/PRME
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT Margin of Prime Medicine, Inc.
Most recent EBIT Marginof PRME including historical data for past 10 years.Interactive Chart of EBIT Margin of Prime Medicine, Inc.
Prime Medicine, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2023 | 0.0% | 0.0% | 0.0% | – | – |
2022 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
2021 | – | – | – | 0.0% | 0.0% |
2020 | – | – | – | – | -17.89% |
Business Profile of Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology